EVERSANA INTOUCH’s Post

Thoughts on this? >> Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharmaceutical #pharma

Thoughts on this? >> Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #competitivemarketing #biotech #healthcare

Thoughts on this? >> Gilead, with approval in sight, shows $4.3B liver disease drug improves outcomes out to 2 years >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #pharmaceutical #healthcare #biotech

Patient Engagement in the Pharmaceutical Industry is already an important standard in today. An interesting overview of the positions of several companies can be found here: https://lnkd.in/diJiWZhU Enjoy reading.

Thoughts on this? >> Gilead, with approval in sight, shows $4.3B liver disease drug improves outcomes out to 2 years >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #competitivemarketing

In a significant development towards improving the lives of people with Multiple Sclerosis (MS), the FDA has approved the first biosimilar for this chronic autoimmune disease. This breakthrough promises to transform the treatment of MS, making it more affordable and accessible for patients who previously relied on expensive therapies like Tysabri. The newly approved biosimilar mimics the effects of Tysabri and is a major milestone in biopharmaceuticals. It offers an alternative to the brand-name medication, which has the potential to significantly reduce treatment costs, making it more affordable for patients and healthcare systems. Read more about the approval below. #Artemisfactor #pharmaceuticals #biotechnology #healthcare #womeninscience

[Celltrion's Zymfentra makes US debut] Korean biopharmaceuticals firm Celltrion Inc announced Monday that its new autoimmune disease treatment Zymfentra has been launched in the US market. Zymfentra is a subcutaneous injection formulation of Celltrion's infliximab Remsima. In October last year, the US Food and Drug Administration approved Zymfentra (infliximab-dyyb) for the maintenance treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease. "Infliximab is a well-established treatment for people living with ulcerative colitis or Crohn's disease," said Thomas Nusbickel, chief commercial officer at Celltrion USA. "The novel subcutaneous administration represents an important advancement in patient care that can offer a convenient treatment option, allowing patients in the US to have greater flexibility in managing their disease." Celltrion said the wholesale acquisition cost of two injections of Zymfentra, which a patient needs in four weeks, has been set at $6,181. “The company has been able to set an optimal price for the drug considering the prices of its competing products,” Celltrion said. Tap below to read full story. #Celltrion #Zymfentra #drug #biotech #bio #patient #US #pharmaceutics https://lnkd.in/gxQnMXg5

An old one but a good one nonetheless. Successfully launching a rare disease drug in a patient-centric world requires a true commitment to understanding and engaging with the rare disease community in order to foster innovative methods for patient identification, strategically navigating patient access, and provide comprehensive support for patients and caregivers throughout their treatment journey. The core focuses of pharmaceutical companies haven't changed much, though I'd say that thanks to a rise in AI/ML, there has been an increase in the prominence and utilization of real-world data and evidence. Because the underlying drivers and pillars are still largely the same as they were a few years ago, we're likely going to see a complete shift in patient experience, driven by advancements in treatment accessibility, engagement, and real-world evidence generation, ultimately reshaping the landscape of rare disease therapeutics. #RareDiseases #DrugDevelopment #PatientCare #Healthcare

Biogen needs Leqembi to be successful following discontinuation of Aduhelm, says GlobalData "Biogen focuses on the success of Leqembi after discontinuing Aduhelm. The firm's strategic shift is noteworthy in the healthcare field. Reinforcing its position in the market, it's a pivotal moment for Biogen." #Biogen #Leqembi #HealthcareIndustry #Pharmaceuticals #MarketStrategy #ProductDevelopment #pharma #biotech #pharmiwebcom

#biologics in #asthma can be a game changer for some people, especially for the 20% that can expect to achieve remission. Unfortunately, an equal 20% don't see a measurable response, and the remaining 60% still have symptoms and reduced lung function. At $50,000 per year plus the inhalers that 80% of patients still need, this is very expensive problem for individuals, families, and government and employer based payers. Supported self-management programs, like NuvoAir Medical, are extremely effective at a fraction of the price: https://lnkd.in/giMFc28Y But cost effective care doesn't have the marketing budget that pharma does. . Somehow pharmaceuticals